Trevi Therapeutics announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO), effective September 30, 2024. Dr. Cassella previously served on Trevi's Board of Directors for four years.
Dr. Cassella brings over 35 years of experience in drug and product development, with a specific focus on central nervous system (CNS) therapies. His prior roles include spearheading the successful US FDA approval of Leqselvi™ at Concert Pharmaceuticals and Adasuve™ at Alexza Pharmaceuticals.
This appointment is expected to play an integral role in progressing Haduvio through its pivotal development program in IPF, advancement in refractory chronic cough, and preparation for regulatory submission. Dr. Cassella replaces Dr. David Clark, who stepped down as Chief Medical Officer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.